Stem cells

Deep 6 AI Announces Substantial Expansion of its Innovative AI-Based Clinical Trial Acceleration Software and Research Ecosystem

Retrieved on: 
Tuesday, June 29, 2021
Biotechnology, FDA, Alternative medicine, Diabetes, AIDS, Health, Surgery, Teens, Other Science, Stem cells, Other Technology, Research, Practice Management, Physical therapy, Software, Managed care, General Health, Other Consumer, Women, Seniors, Data management, Technology, MEN, Family, Other Health, Consumer, Radiology, Pharmaceutical, Optical, Oncology, Mental health, Medical devices, Infectious diseases, Hospitals, Genetics, Fitness & Nutrition, Science, Dental, Veterinary, Clinical trials, Nursing, Cardiology, Medical Supplies, Academic disciplines, Articles, Health sciences, Pharmaceutical industry, Clinical trials, Clinical research, Computational neuroscience, Food and Drug Administration, Artificial intelligence, Patient recruitment

Deep 6 AI, the leader in artificial intelligence (AI)-based clinical trial acceleration software (CTAS), today announced significant growth with the addition of key customer wins and an expanding executive leadership team.

Key Points: 
  • Deep 6 AI, the leader in artificial intelligence (AI)-based clinical trial acceleration software (CTAS), today announced significant growth with the addition of key customer wins and an expanding executive leadership team.
  • I started Deep 6 AI in 2016 to use the power of AI to rethink patient recruitment and trial feasibility in clinical research, said Wout Brusselaers, CEO of Deep 6 AI.
  • Deep 6 AI develops clinical trial acceleration software to bring the right therapies to patients faster.
  • The platform connects sponsors, clinical researchers, physicians, and patients in a rapidly growing real-world ecosystem of premier research organizations.

Selexis and KBI Biopharma Enter into Agreements with Immatics for Integrated Approach to Advance Immatics TCR Bispecific Program Towards IND

Retrieved on: 
Tuesday, June 29, 2021
Oncology, Health, Stem cells, Genetics, Pharmaceutical, Biotechnology, Bispecific monoclonal antibody, CGMP

Under the agreements, Selexis will utilize its SUREtechnology Platform and KBI will leverage its advanced analytics, process, formulation and cGMP manufacturing for Immatics IMA402 program.

Key Points: 
  • Under the agreements, Selexis will utilize its SUREtechnology Platform and KBI will leverage its advanced analytics, process, formulation and cGMP manufacturing for Immatics IMA402 program.
  • Working together to support Immatics provides us a significant opportunity to demonstrate the power of our integrated expertise.
  • Were excited to work with Immatics as the company advances its TCR Bispecific candidate IMA402 towards the clinic.
  • We have chosen Selexis and KBI because of their expertise in the development and manufacturing of bispecific antibodies.

Boston Children’s Hospital and ElevateBio Announce Five-Year Cell and Gene Therapy Collaboration

Retrieved on: 
Tuesday, June 29, 2021
Stem cells, Biotechnology, Other Health, Health, General Health, Pharmaceutical, Other Science, Research, Hospitals, Genetics, Science, Harvard Medical School, Boston Children's Hospital, Children's Hospital Colorado, Stem cell research, Hospitals, Colorado, Healthcare in the United States, Boston Children’s Hospital:, ElevateBio, BOSTON CHILDREN’S HOSPITAL:, ELEVATEBIO

Boston Childrens Hospital, which has the largest National Institutes of Health-funded pediatric research enterprise in the United States, and ElevateBio, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, today announced that they have entered into a five-year collaborative agreement to advance cell and gene therapy programs originating out of Boston Childrens Hospital with an introduction to Boston Childrens translational research capabilities.

Key Points: 
  • Boston Childrens Hospital, which has the largest National Institutes of Health-funded pediatric research enterprise in the United States, and ElevateBio, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, today announced that they have entered into a five-year collaborative agreement to advance cell and gene therapy programs originating out of Boston Childrens Hospital with an introduction to Boston Childrens translational research capabilities.
  • The agreement enables Boston Childrens and ElevateBio to form multiple cell and gene therapy companies together; provides Boston Childrens researchers access to ElevateBios core-enabling technologies, manufacturing, and leading expertise to advance their programs; and will guarantee Boston Childrens researchers dedicated viral-vector manufacturing space at ElevateBio BaseCamp, ElevateBios centralized world-class research and development manufacturing center.
  • At Boston Childrens Hospital, we are proud of the foundation weve established as a leading innovator in cell and gene therapy, so collaborating with ElevateBio a company so well-positioned to change the face of cell and gene therapy forever is a natural fit into our overall vision, said David Williams, M.D., formerly Senior Vice President for Research and Chief Scientific Officer, currently Chief of Hematology / Oncology, Boston Children's Hospital.
  • Boston Childrens Hospital has a strong history of innovation in the cell and gene therapy sector through ground-breaking science and spinning out companies to deliver medicines to patients.

Orbit Discovery Appoints Dr Neil Butt as Chief Executive Officer

Retrieved on: 
Tuesday, June 29, 2021
Biotechnology, Health, Genetics, Stem cells, Pharmaceutical, Peptide

Orbit Discovery Ltd (Orbit), a biopharmaceutical company focused on discovering candidate peptide therapeutics using high throughput microfluidic platforms, has announced the appointment of Dr Neil Butt as Chief Executive Officer.

Key Points: 
  • Orbit Discovery Ltd (Orbit), a biopharmaceutical company focused on discovering candidate peptide therapeutics using high throughput microfluidic platforms, has announced the appointment of Dr Neil Butt as Chief Executive Officer.
  • With an extensive track record in commercialising proprietary drug discovery platforms, Dr Butt joins Orbit to oversee the Companys development into a service driven drug discovery company, with a focus on identifying candidate peptides against challenging targets, such as G-protein coupled receptors (GPCRs).
  • Prior to joining Orbit, Dr Butt most recently served as on the board and as Chief Business Officer of IONTAS, a privately held company exploiting mammalian display technology in the discovery of novel antibodies with inherent biophysical properties that align with speedy progression through manufacturing.
  • Dr Neil Butt, CEO Orbit Discovery, said: I believe Orbit Discovery is poised to exploit the challenging area of membrane spanning therapeutic peptides and proteins.

Americord Hires Ankur Gandhi, Ph.D. as Vice President, Research & Development and Lab Management

Retrieved on: 
Monday, June 28, 2021
Stem cells, Blood, Branches of biology, Biology, Ankur, Cord blood

NEW YORK, June 28, 2021 /PRNewswire/ -- Americord Registry is announcing the hiring of Ankur Gandhi, Ph.D.as Vice President, Research & Development and Lab Management.

Key Points: 
  • NEW YORK, June 28, 2021 /PRNewswire/ -- Americord Registry is announcing the hiring of Ankur Gandhi, Ph.D.as Vice President, Research & Development and Lab Management.
  • Ankur joins Americord after serving as Director of Research & Development at Integra Lifesciences , where he was responsible for the establishment of product pipeline strategy and the development and commercialization of regenerative medicine products across multiple franchises.
  • That experience will prove valuable as Americord continues to drive innovation in the cord blood banking and life sciences industry.
  • Martin Smithmyer, Founder and CEO, said, "Ankur is joining Americord at a time when leadership in R&D is needed.

Eikonoklastes Closes Oversubscribed Series A Financing, Helping to Advance Immunotherapies Toward Clinical Trial Stage

Retrieved on: 
Monday, June 28, 2021
Oncology, Health, Stem cells, Genetics, Pharmaceutical, Biotechnology, Pharmaceutical industry, Medication

The therapies also have the potential to address several other non-cancer diseases with significant unmet clinical need.

Key Points: 
  • The therapies also have the potential to address several other non-cancer diseases with significant unmet clinical need.
  • Details of the financing were not disclosed, but Eikonoklastes Chief Executive Officer, Bruce Halpryn, Ph.D., said the initial target was significantly oversubscribed.
  • The Series A financing positions the company to continue forging ahead towards bringing much needed new medicines to patients.
  • These novel and proprietary molecules are the third generation of technology that Dr. Hu initially designed while at Yale University.

Kite Announces Yescarta® CAR T-cell Therapy Improved Event-Free Survival by 60% Over Chemotherapy Plus Stem Cell Transplant in Second-Line Relapsed or Refractory Large B-cell Lymphoma

Retrieved on: 
Monday, June 28, 2021
Research, Hospitals, Clinical trials, Stem cells, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Clinical medicine, Medicine, Health sciences, Gene therapy, Orphan drugs, Gilead Sciences, Breakthrough therapy, Immune system, Brexucabtagene autoleucel, Chimeric antigen receptor T cell, Lymphoma, Kite Pharma

Event-free survival is defined as time from randomization to disease progression, commencement of new lymphoma therapy, or death from any cause.

Key Points: 
  • Event-free survival is defined as time from randomization to disease progression, commencement of new lymphoma therapy, or death from any cause.
  • ZUMA-7 evaluated an one-time infusion of the CAR T-cell therapy Yescarta compared to SOC in adult patients with relapsed or refractory LBCL.
  • Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
  • Kite, the Kite logo, Yescarta, Tecartus, XLP and GILEAD are trademarks of Gilead Sciences, Inc. or its related companies.

Captivate Bio Signs Exclusive Distribution Agreement with PL BioScience Across North America

Retrieved on: 
Monday, June 28, 2021
Biotechnology, Health, Science, Stem cells, Research, Branches of biology, Biology, Cell biology, Blood, Platelet lysate, Adobe Captivate, Biotechnology, Platelet, BIOS, Cell culture, PL BioScience, Captivate Bio, PL BIOSCIENCE, CAPTIVATE BIO

Captivate Bio, a scientific cell culture solutions provider, today announced it has signed an exclusive distribution agreement with PL BioScience GmbH, a biotech company located in Aachen, Germany, to bring its portfolio of human platelet lysate to markets across North America.

Key Points: 
  • Captivate Bio, a scientific cell culture solutions provider, today announced it has signed an exclusive distribution agreement with PL BioScience GmbH, a biotech company located in Aachen, Germany, to bring its portfolio of human platelet lysate to markets across North America.
  • Captivate Bio will supply all ELAREM human platelet lysate product lines for sale in the US and Canada from its headquarters in Watertown, Massachusetts.
  • This agreement provides great upside potential for Captivate Bio and adds value for our customers with more options for HPL, stated Tanya Potcova, Captivate Bios co-founder and CEO.
  • We highly value Captivate Bios experience in the commercialization of cell culture media and we look forward to joining forces across North America.

Sana Biotechnology Presents Data at ISSCR 2021 Virtual Annual Meeting Showing Survival of Transplanted Hypoimmune Stem Cells Without Immunosuppression in Non-Human Primates

Retrieved on: 
Saturday, June 26, 2021
Branches of biology, Biology, Life sciences, Induced stem cells, Stem cells, Biotechnology, Cell biology, Developmental biology, Induced pluripotent stem cell, IPSCS, Immunosuppression

SEATTLE, June 26, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today presented data showing survival of transplanted stem cells without immunosuppression in non-human primates (NHPs).

Key Points: 
  • SEATTLE, June 26, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today presented data showing survival of transplanted stem cells without immunosuppression in non-human primates (NHPs).
  • The transplanted cells were induced pluripotent stem cells (iPSCs) with Sanas hypoimmune gene modifications that enable immune evasion.
  • Sanas hypoimmune (HIP) platforms goal is to eliminate the need for immunosuppression by cloaking cells from immune recognition.
  • Sana Biotechnology and the Sana Biotechnology logo are trademarks of Sana Biotechnology, Inc. or its subsidiaries.

Alphageneron to Participate in the ROTH Virtual Healthcare Private Company Forum on June 28th, 2021

Retrieved on: 
Saturday, June 26, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Stem cells, Cell biology, Induced stem cells, Immune system, Natural killer cell, Induced pluripotent stem cell, Cell therapy, IPSCS

CAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) -- Alphageneron Pharmaceuticals, Inc. (Alphageneronor theCompany), a privately-held clinical-stage biopharmaceutical company developing autologous and allogeneic Natural Killer (NK) cellular and antibody therapeutics announced that Robert Brooks, JD, founder and Chief Executive Officer of Alphageneron, will participate in the ROTH Healthcare Private Company Forum to be hosted virtually on Monday, June 28, 2021.

Key Points: 
  • CAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) -- Alphageneron Pharmaceuticals, Inc. (Alphageneronor theCompany), a privately-held clinical-stage biopharmaceutical company developing autologous and allogeneic Natural Killer (NK) cellular and antibody therapeutics announced that Robert Brooks, JD, founder and Chief Executive Officer of Alphageneron, will participate in the ROTH Healthcare Private Company Forum to be hosted virtually on Monday, June 28, 2021.
  • Alphageneron is also planning a Phase I clinical Combination trial with Metastatic Colorectal cancer withallogeneic donor genetically edited NK cell therapy, (ANKASTIM) in the United States.
  • To register for this virtual event click www.roth.com/healthcareprivateday or please contact Gerald Roger, c/o Trinity Capital Advisers Tel.
  • Alphageneron is also developing allogeneic Induced pluripotent stem cells (iPSCs) CAR-engineered NK (CAR NK) cells to an undisclosed target.